These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28426179)

  • 1. Novel, Selective, and Developable Dopamine D
    Micheli F
    ChemMedChem; 2017 Aug; 12(16):1254-1260. PubMed ID: 28426179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.
    Micheli F; Bacchi A; Braggio S; Castelletti L; Cavallini P; Cavanni P; Cremonesi S; Dal Cin M; Feriani A; Gehanne S; Kajbaf M; Marchió L; Nola S; Oliosi B; Pellacani A; Perdonà E; Sava A; Semeraro T; Tarsi L; Tomelleri S; Wong A; Visentini F; Zonzini L; Heidbreder C
    J Med Chem; 2016 Sep; 59(18):8549-76. PubMed ID: 27564135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.
    Micheli F; Bernardelli A; Bianchi F; Braggio S; Castelletti L; Cavallini P; Cavanni P; Cremonesi S; Dal Cin M; Feriani A; Oliosi B; Semeraro T; Tarsi L; Tomelleri S; Wong A; Visentini F; Zonzini L; Heidbreder C
    Bioorg Med Chem; 2016 Apr; 24(8):1619-36. PubMed ID: 26951894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of indolebutylamines as a novel class of selective dopamine D3 receptor ligands.
    Du P; Xu L; Huang J; Yu K; Zhao R; Gao B; Jiang H; Zhao W; Zhen X; Fu W
    Chem Biol Drug Des; 2013 Sep; 82(3):326-35. PubMed ID: 23663349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.
    Micheli F; Cremonesi S; Semeraro T; Tarsi L; Tomelleri S; Cavanni P; Oliosi B; Perdonà E; Sava A; Zonzini L; Feriani A; Braggio S; Heidbreder C
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1329-32. PubMed ID: 26786693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors.
    Michino M; Free RB; Doyle TB; Sibley DR; Shi L
    Chem Commun (Camb); 2015 May; 51(41):8618-21. PubMed ID: 25896577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D
    Appiah-Kubi P; Olotu FA; Soliman MES
    J Mol Recognit; 2021 May; 34(5):e2885. PubMed ID: 33401335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.
    Austin NE; Avenell KY; Boyfield I; Branch CL; Hadley MS; Jeffrey P; Johnson CN; Macdonald GJ; Nash DJ; Riley GJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Wood MD
    Bioorg Med Chem Lett; 2001 Mar; 11(5):685-8. PubMed ID: 11266169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.
    Brown DA; Kharkar PS; Parrington I; Reith ME; Dutta AK
    J Med Chem; 2008 Dec; 51(24):7806-19. PubMed ID: 19053758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
    Cai J; Huang M; Wang Y; Chen X; Ji M
    Bioorg Med Chem Lett; 2021 Sep; 48():128269. PubMed ID: 34284107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3-azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists.
    Micheli F; Hamprecht D; Bonanomi G; Di Fabio R; Donati D; Gentile G; Heidbreder C; Prandi A; Tarsi L; Terreni S
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5491-4. PubMed ID: 20692836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.
    Micheli F
    ChemMedChem; 2011 Jul; 6(7):1152-62. PubMed ID: 21425240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
    J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
    Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPCR targeted library design: novel dopamine D3 receptor ligands.
    Böcker A; Sasse BC; Nietert M; Stark H; Schneider G
    ChemMedChem; 2007 Jul; 2(7):1000-5. PubMed ID: 17477344
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.
    Rangel-Barajas C; Malik M; Mach RH; Luedtke RR
    Neuropharmacology; 2015 Jun; 93():179-90. PubMed ID: 25698528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.